Tofacent XR Tablet (Extended Release)

Introduction

Tofacent XR Tablet (Extended Release) 11 mg is an inhibitor of the Janus kinase (JAK) family of enzymes. It is used to treat rheumatoid arthritis (RA) and psoriatic arthritis. It works by inhibiting the activation of signal transduction proteins involved in the overproduction of pro-inflammatory proteins. It is classified as a "biologic" medication, meaning that it is made up of genetically engineered proteins.

Uses

Tofacent XR Tablet (Extended Release) 11 mg is used to treat adults with active rheumatoid arthritis (RA). It can also be used to treat psoriatic arthritis in adults. Tofacent XR Tablet (Extended Release) 11 mg can reduce the signs and symptoms of RA and help improve physical function.

Brand Name	Tofacent XR
Type	Tablet (Extended Release)
Weight	11 mg
Generic	Tofacitinib
Manufacturer	Incepta Pharmaceuticals Ltd.
Available in	English বাংলা

Mechanism of Action

Tofacent XR Tablet (Extended Release) 11 mg works by inhibiting the Janus kinase (JAK) family of enzymes. JAKs are involved in the activation of signal transduction proteins involved in the overproduction of pro-inflammatory proteins. By inhibiting the action of the JAKs, tofacitinib decreases the production of these pro-inflammatory proteins, relieving the symptoms of RA and psoriatic arthritis.

How Long Does it Take to Work?

The time it takes for tofacitinib to show its effects varies from person to person. Most patients experience relief of RA symptoms within 2 to 3 weeks of initiation of treatment. This duration may be shorter or longer in some individuals.

Absorption

Tofacent XR Tablet (Extended Release) 11 mg is rapidly absorbed after oral consumption with a median of 1 hour. The drug is readily absorbed from the gastrointestinal tract, with no evidence of altered absorption due to food intake.

Route of Elimination

Tofacent XR Tablet (Extended Release) 11 mg is primarily eliminated via metabolism in the liver. The metabolites of tofacitinib are excreted via urine and bile.

Dosage

Rheumatoid Arthritis: Tofacitinib 5 mg twice daily or Tofacitinib 11 mg once daily. Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is Tofacitinib 5 mg once daily.

Psoriatic Arthritis (in combination with nonbiologic DMARDs): Tofacitinib 5 mg twice daily or Tofacitinib 11 mg once daily. Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is Tofacitinib 5 mg once daily.

Ulcerative Colitis: Tofacitinib 10 mg twice daily for at least 8 weeks; then 5 or 10 mg twice daily. Discontinue after 16 weeks of 10 mg twice daily, if adequate therapeutic benefit is not achieved. Use the lowest effective dose to maintain response.

Tofacent XR Tablet (Extended Release) 11 mg is available in 5 mg, 10 mg, 15 mg, and 30 mg tablets and is taken orally, usually twice daily. Patients may start with a lower dose and increase it gradually depending on their response and tolerance. The maximum recommended daily dose is 15 mg twice daily. The dose should be reduced in patients with impaired renal function.

Administration

Tofacent XR Tablet (Extended Release) 11 mg should be taken orally, with or without food, usually twice daily. It should be taken at the same time each day as prescribed by the physician. It is important to take tofacitinib exactly as prescribed by the doctor.

Side Effects

The common side effects associated with tofacitinib use are gastrointestinal upset, headaches, low blood pressure, and elevated liver enzymes. Serious side effects associated with tofacitinib include increased risk of infection, worsening of the underlying disease, and increased risk of blood clots.

Toxicity

Tofacent XR Tablet (Extended Release) 11 mg has not been associated with any reported cases of toxicity in humans. However, due to its mechanism of action, it may lead to increased susceptibility to certain infections.

Precaution

Tofacent XR Tablet (Extended Release) 11 mg should be used with caution in patients with impaired renal function. It is important to monitor patients closely for signs and symptoms of infection and worsening of the underlying disease. Patients should be advised to inform their doctor if they develop any signs or symptoms of infection.

Interaction

Tofacent XR Tablet (Extended Release) 11 mg may interact with other medications, including warfarin, cyclosporine, antifungal medications, and methotrexate. It is important for patients to inform their doctor about any medications they may be taking prior to starting tofacitinib.

Disease Interaction

Tofacent XR Tablet (Extended Release) 11 mg may interact with other diseases, including certain types of cancer, making them more likely to recur or worsen. It is important to discuss any existing medical conditions with the doctor prior to starting tofacitinib.

Drug Interaction

Tofacent XR Tablet (Extended Release) 11 mg may interact with other drugs, affecting their effectiveness or increasing their potential side effects. It is important to inform the doctor of any medications the patient is taking prior to starting tofacitinib, and to continue to monitor for possible interactions during treatment.

Food Interactions

Tofacent XR Tablet (Extended Release) 11 mg is not known to interact with food.

Pregnancy Use

Tofacent XR Tablet (Extended Release) 11 mg has not been studied in pregnant women. It is important to discuss the risks and benefits of taking tofacitinib with the doctor prior to considering use during pregnancy.

Lactation Use

Data regarding the use of tofacitinib in lactating mothers is lacking. Therefore, it is important to discuss the risks and benefits of taking tofacitinib with the doctor prior to considering use while breastfeeding.

Acute Overdose

No cases of acute overdose of tofacitinib have been reported. However, due to its mechanism of action, it is important to contact a doctor or seek emergency medical help if too much occurs.

Contraindication

Tofacent XR Tablet (Extended Release) 11 mg is contraindicated in patients with a known hypersensitivity to tofacitinib or any of its components. It is also contraindicated in patients with active serious infections or a history of severe infections.

Use Direction

Tofacent XR Tablet (Extended Release) 11 mg should be taken exactly as prescribed by the doctor. The dose may be increased or decreased depending on the response and tolerance. It is important to take it at the same time each day with or without food.

Storage Condition

Tofacent XR Tablet (Extended Release) 11 mg should be stored at room temperature, away from direct light and moisture. It should not be exposed to extremes of temperature.